INTRODUCTION
Hematopoiesis is initiated by multipotent hematopoietic stem cells (HSCs) . The blood-forming system is able to respond efficiently to hematological stresses such as bleeding, inflammation, or exposure to irradiation or cytotoxic agents by expanding the HSC population (Heissig et al., 2005b) . Thus, HSC proliferation and differentiation must be highly adaptive to ensure both a durable production of progenitor populations during steady-state hematopoiesis and extensive, stress-induced proliferation without depletion of the stem cell pool. A major challenge in stem cell biology is to elucidate the factors contributing to this fine-tuned adaptation to stress or cell loss.
The bone marrow (BM) is the primary hematopoietic site in the adult. For example, the BM stromal compartment harbors extracellular matrix (ECM) and cytokines that are capable of influencing self-renewal, proliferation, and differentiation of hematopoietic stem and progenitor cells (HSPCs) .
The serine protease plasmin plays an important role in fibrinolysis and can degrade ECM molecules (Herren et al., 2003) . Plasminogen (Plg), its inactive proenzyme, can be activated by tissue-type plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), and other serine proteases. Mice with homozygously disrupted Plg genes are predisposed to severe thrombosis and develop intraand extravascular fibrin deposition in many tissues (Bugge et al., 1995) . During fibrinolysis, plasmin can participate in the consecutive activation of matrix metalloproteinases (MMPs) (Lijnen et al., 1998b; Liu et al., 2005) .
In this study, we provide mechanistic data demonstrating that Plg À/À mice exhibit defects in hematopoietic reconstitution after myelosuppression, owing to a defect in HSPC proliferation. The absence of Plg results in impaired long-term survival after BM transplantation.
RESULTS

Plasmin Generation Is Required for Hematopoietic Regeneration
We took advantage of mice with homozygously disrupted Plg genes (Bugge et al., 1995) and a model of stress hematopoiesis to investigate the role of Plg in hematopoiesis. We stained BM sections for Plg during the early recovery phase (2 or 3 days after myelosuppression) after chemotherapy and found positively stained areas along bonelining cells ( Figure 1A ). We therefore hypothesized that plasmin(ogen) regulates hematopoietic reconstitution after myelosuppression. Myelosuppression induced by 5-fluorouracil (5-FU) results in apoptosis of cycling HSPCs but does not affect HSCs in G 0 . All Plg À/À mice receiving 5-FU succumbed by day 10 after 5-FU injection, whereas Plg +/+ mice survived the 5-FU treatment ( Figure 1B ) and exhibited recovery of white blood cells (WBCs) ( Figure 1C ), platelets (see Figure S1A in the Supplemental Data available with this article online) and BM cells ( Figure 1D ). During hematopoietic regeneration, quiescent (G 0 /G 1 ) stem cells enter the cell cycle and can differentiate.
Regeneration of total CD11b+/Gr-1+ myeloid BM cells ( Figure 1E ) and immature megakaryocyte progenitors at the 2N and 4N stage ( Figure S1B ) occurred in the Plg +/+ mice, but not in Plg À/À mice. Hematopoietic recovery was delayed in Plg À/À mice as compared to Plg +/+ mice ( Figure 1F ). Although the percentage of Sca-1+ cells in S phase of the cell cycle was similar in Plg +/+ and Plg À/À mice under steady-state conditions ( Figure 1G ), fewer Sca-1+ cells shifted into S phase in Plg À/À mice as compared to wild-type (WT) cells upon myelosuppression. Thus, cell-cycle transition and the stress-induced cell regeneration did not occur in Plg-deficient mice. Treatment with 5-FU did not result in death of mice singly deficient in uPA (n = 5), tPA (n = 5), or urokinase plasminogen activator receptor (uPAR) (n = 6) (data not shown). However, one out of three uPA/tPA double-deficient mice died within the first few days after 5-FU injection (data not shown).
Plg-Mediated Activation of MMPs in the BM Promotes the Release of KitL
Plg activation can lead to activation of MMPs, especially MMP-9 (Lijnen et al., 1998b) . We found higher levels of proMMP-2 and proMMP-9 but, more importantly, active MMP-9 in supernatants of equal numbers of cultured BM cells derived from Plg +/+ animals 5 and 10 days after 5-FU treatment, as compared to Plg À/À mice ( Figure 2A ). Levels of immunoreactive proMMP-9 were attenuated in BM ( Figure 2B ), and less active MMP-9 was found in the plasma of Plg À/À mice treated with 5-FU ( Figure 2C ). If plasmin activates MMPs, then plasma levels of KitL, a cytokine implicated in hematopoietic regeneration that can be regulated by MMP-9 , should be low in Plg À/À mice after 5-FU treatment, as indeed was the case ( Figure 2D ). We could implicate the lack of hematopoietic recovery after myelosuppression to impaired release of KitL in Plg À/À mice because daily injections of recombinant KitL partly restored the survival of Plg À/À mice ( Figure 2E ) and promoted BM cell recovery (Figures 2F and 2G Figure 3B ). We reasoned that tPA, through activation of Plg, indirectly could activate MMPs in BM stromal cells. Active MMP-9 and MMP-2 were detectable by zymography in MS-5 ( Figure 3C ) and freshly isolated lin+ cells from Plg +/+ animals ( Figure 3D ) incubated with recombinant tPA. Immunoreactive Plg was detectable 1 hr after injection of recombinant tPA in close vicinity to sinusoidal BM vessels ( Figure 3E ), while hematopoietic and stroma cells throughout the BM of tPA-treated animals expressed immunoreactive MMP-9 ( Figure 3F ).
tPA Treatment Augments the Release of Soluble KitL Since activation of MMP-9 modulates the c-Kit/KitL pathway , we assessed whether tPA promotes KitL release, which could drive hematopoietic regeneration. tPA treatment augmented the release of KitL from MS-5 cells ( Figure 3G ) and primary BM stromal cells ( Figure 3H ). Of importance, the tPA-mediated release of KitL from stromal cells took place via MMP activation: addition of a MMP inhibitor inhibited KitL release from stromal cells. When MS-5 cells were treated with PAI-1, the natural inhibitor of tPA, KitL release was lower than in control supernatants. If Plg is important for KitL release and tPA converts Plg into plasmin, increased KitL plasma levels should be found in tPA-treated animals, which indeed was the case ( Figure 3I ). Similarly, KitL levels rose above baseline levels after tPA treatment, even in Plg À/À mice. Nonenzymatic mutant tPA has been reported to induce MMP-9 expression, suggesting that some actions of tPA are independent of its proteolytic activity (Hu et al., 2006) . When MMP-deficient mice were injected with tPA, KitL plasma levels did not rise, indicating that tPA-mediated KitL release required MMP-9 activation ( Figure 3I ). KitL in combination with other cytokines can push quiescent stem cells into cell cycle. More linÀ/Sca-1/c-Kit+ BM cells entered the S phase of the cell cycle in BM cells of tPA-treated mice as compared to carrier-treated animals ( Figure 3J ). These data indicate that administration of tPA leads to activation of MMPs, necessary for the release of KitL from BM stromal cells. KitL in turn pushes noncycling cells into cell cycle.
tPA Promotes Erythroid, Myelomonocytic, and Megakaryocytic Cell Differentiation Committed erythroid cells undergo several steps of differentiation from erythroid progenitors, forming EPO-responsive erythroblasts, which differentiate ultimately to erythrocytes. Erythroid differentiation can be monitored by using the markers CD71 and Ter119 (Socolovsky et al., 2001 (Lagasse and Weissman, 1996) . We assessed CD11b and Gr-1 expression in adult BM with flow cytometry. The absolute number of CD11b+Gr-1 hi cells decreased in tPA-treated mice on day 1 and to a lesser extent on day 3, whereas CD11b+Gr-1 lo cells increased as compared to untreated animals (0.36 ± 0.007 versus 0.51 ± 0.01 3 10 7 on day 1).
The differentiation of megakaryocytes is characterized by polyploidization and cytoplasmic maturation leading to platelet production. The percentage of polyploid megakaryocytese of 32 and 64N ploidy increased in tPA-treated mice as compared to controls ( Figure S1C ). These data indicate that administration of tPA promotes erythroid, myelomonocytic, and megakaryocytic cell differentiation in vivo. But further studies will be needed to understand the underlying mechanism.
tPA-Mediated HSPC Expansion Requires the Presence of KitL
To assess whether tPA can act as a hematopoietic cytokine, we evaluated HSPC expansion both in vitro and in vivo. tPA administration in vivo augmented the number of BM cells in WT controls, but this was attenuated in both Plg-deficient and MMP-9-deficient mice ( Figure 4A ). tPA increased the number of spleen colony-forming units day 8 (CFU-Sd8, Figure 4B ), of long-term culture-initiating cells (LTC-IC, Figure 4C ), and of the c-Kit+/Sca-1+/linÀ (KSL) cell fraction in BM cells of treated animals ( Figure 4D ). Long-term injection of tPA kept BM cell numbers persistently elevated above steady-state values ( Figure 4E ). These data indicate that tPA, through activation of Plg, influences progenitor cell proliferation.
KitL can expand hematopoietic CFCs of multiple types in the BM (Andrews et al., 1992) and increase marrow cellularity. To test if tPA-mediated hematopoietic cell proliferation is dependent on KitL in vivo, we treated KitL-deficient Sl/Sl d mice and WBB6F1 +/+ control mice with tPA. BM cellularity ( Figure 4F ) and the number of immature CFU-Sd8 progenitor cells ( Figure 4G ) increased in WBB6F1 as compared to Plg +/+ mice (0.018% ± 0.001% versus 0.051% ± 0.005%; n = 9, p < 0.0001). Even though LTC-IC, CFUSd8, and SP cells show enrichment for HSCs, they still contain a significant number of progenitor cells. For example, the SP cell fraction is enriched between 1000-fold and 3000-fold for HSCs (Goodell et al., 1996) .
To date, transplantation assays are still regarded as the most stringent assay for the quantification of stem cells. To ensure that the decreased number of progenitor cells was due to extrinsic factors (e.g., the lack of KitL within the hematopoietic microenvironment) rather than an intrinsic stem cell defect, we performed competitive repopulation experiments with the congenic CD45.1/CD45.2 alleles to distinguish donor and competitor cells. Figure S1E ). These data indicate that Plg-deficient mice do not have a functional HSC but rather a progenitor cell defect.
Plg and MMP-9 Are Necessary for tPA-Mediated BM Reconstitution To address the question of whether tPA-mediated hematopoiesis requires Plg and/or MMP-9, we treated Plg-and MMP-deficient with 5-FU on day 0 followed by daily injections with or without recombinant tPA. tPA did not improve survival ( Figure 5A ), recovery of WBC ( Figure 5B ), or the number of BM cells ( Figure 5C ) in Plg À/À mice. Of interest, stronger Plg/plasmin staining was detectable by immunohistochemistry after the administration of recombinant tPA into Plg +/+ mice in BM areas close to the bone ( Figure 5D ). To elucidate why tPA-treated Plg +/+ mice showed faster BM recovery and higher leukocyte counts, we examined BM cell myelograms. In myelogram analysis, percentages of late myeloid cells, such as neutrophils and metamyelocytes, increased in tPA-treated mice as compared with nontreated littermates ( Figure 5E ). Similarly, the number of erythroblasts increased at the expense of the more immature proerythroblasts ( Figure 5F ). tPA did not promote cell differentiation in Plg À/À mice (data not shown).
Similarly, in 5-FU-treated MMP-9-deficient mice, the recovery of BM cells ( Figure 5G ) or WBCs ( Figure 5H ) was delayed, and death after 5-FU ( Figure 5I ) could not be rescued/prevented using daily injections of recombinant tPA. Death occurred in about 70% of MMP-9 À/À mice. Thus, the effect of tPA on hematopoietic reconstitution after myelosuppression requires the presence of both Plg and MMP-9 and possibly other MMPs.
Fibrinolytic Factors Expressed within the BM Promote Hematopoietic Cell Proliferation and Differentiation
To elucidate whether the observed tPA effects on hematopoietic cells were mediated directly by tPA or indirectly, e.g., via BM stromal cells, we examined the effect of tPA Indeed, addition of neutralizing antibodies against c-Kit and/or KitL prevented the tPA-mediated generation of CFU-Cs from linÀ cells in stromal-cell-based cultures ( Figure 6B ). Likewise, addition of PAI-1, the natural inhibitor of tPA to these cultures, abolished tPA-mediated CFU-C formation. Confirming our in vivo data, addition of a synthetic MPI completely blocked progenitor production and prevented tPA-mediated progenitor expansion. These data imply that tPA can modulate progenitor cell expansion by promoting the release of KitL. tPA affected hematopoietic cells only in the presence of stromal cells. So do Plg-deficient mice have a stromal cell defect causing the observed hematopoietic phenotype? When CD45.1 donor cells were transplanted into Plg +/+ or Plg À/À recipients, donor cell contribution to PB leukocytes 80 days after transplantation was lower in Plg À/À than in Plg +/+ recipient mice ( Figure 6C ). This was especially apparent at limiting cell dilutions and correlated with decreased mouse survival at 80 days after transplantation of CD45.1 donor cells in Plg À/À recipient mice ( Figure 6D ). Fewer donor cells were necessary to promote survival in Plg +/+ recipient mice ( Figure 6E ). These data imply that the absence of Plg in the BM is responsible for the reduced hematopoietic cell proliferation in Plg À/À mice.
To overcome the problem of reduced cell proliferation in a Plg-deficient microenvironment, we transplanted very high numbers of BM cells (2 3 10 7 cells/mouse) from Plg À/À or Plg +/+ mice into lethally irradiated Plg À/À or Plg +/+ mice. Under these conditions, all mice survived and showed engraftment after 4 weeks (WBC counts of WT cells transplanted into WT mice 7933 ± 945/mL blood; KO cells into WT mice 7133 ± 1815 ml blood; WT cells into KO mice 6400 ± 1697 ml blood; KO cells into KO mice 7700 ± 1556/mL blood). Then, chimeric mice were treated with the myelosuppressive agent 5-FU. Plg-deficient mice transplanted with either Plg +/+ or Plg À/À BM donor cells succumbed within the first 2 weeks after induction of myelosuppression ( Figure 6F ; n = 9 per group). In contrast, all Plg WT mice transplanted with either Plg +/+ or Plg À/À BM donor cells survived (n = 9 per group), emphasizing a critical role for Plg in the nonhematopoietic BM compartment. We then asked if the impaired survival and cell proliferation 
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Fibrinolytic System Regulates Hematopoiesis of HSPCs within the Plg-deficient BM stromal compartment was due to reduced production of KitL. Lower KitL levels were detected in Plg À/À recipient chimeric mice as compared to Plg +/+ recipient controls ( Figure 6G ). These data underscore the importance of KitL release and maybe other yet-to-be-defined factors from BM stromal cells in a Plg-competent environment for BM reconstitution after myelosuppression with 5-FU. Binding of Plg to fibrin enhances Plg activation (Camiolo et al., 1971) . Immunohistochemical staining of BM sections from WT animals after myelosuppression revealed that, during the hematopoietic regeneration phase, fibrin was found in close vicinity of bone-lining osteoblasts and later in vascular areas, which might be part of the recently proposed vascular niche ( Figure 6H ) (Heissig et al., 2005a) . Fibrin deposition was observed in BM of Plg À/À and, to a lesser extent, Plg +/+ mice after myelosuppressive stress.
Our data indicate that activation of Plg in the regeneration phase after myelosuppression results in an orderly activation of another protease cascade, like MMPs ( Figure 6I ). This proteolytic mixture helps to make growth factors (I) PA-mediated activation of Plg generates plasmin after induction of hematopoietic stress within the BM. Plasmin in turn can activate MMPs, especially MMP-9, thereby releasing chemo/cytokines, like KitL. These factors can regulate the hematopoietic stress response by promoting HSPC proliferation, differentiation, and BM reconstitution. *p < 0.05.
bioavailable, which in a fine-tuned manner can modulate hematopoietic cell proliferation and differentiation.
DISCUSSION
The cellular BM microenvironment mediates the stem cell choice of self-renewal versus differentiation. Whereas self-renewal is important to maintain the stem cell pool, rapid recruitment of HSCs into cell cycle followed by proliferation, and differentiation allows the organism to adapt to hematopoietic stress-cell loss after blood loss or myelosuppression-with the formation of new blood cells. In this study, we provide genetic, functional, and biochemical evidence that the orderly activation of two separate protease systems, the Plg/PA fibrinolytic system and the MMP system after hematopoietic stress, allows hematopoietic cell proliferation and differentiation to take place, a process in part mediated by the release of KitL (Figure 6I) . Collectively, these data introduce a novel paradigm by which fibrinolytic enzymes mediate systemic and localized effects in the BM and establish a novel role for Plg activation in hematopoiesis.
Local Accumulation of Components of the Plasminogen System within the BM
We found local accumulation of Plg/plasmin within the BM stromal compartment after myelosuppression and demonstrated endogenous tPA expression within BM stromal and hematopoietic cells. The presence of fibrinolytic factors within the BM in vivo suggests that localized proteolysis occurs during BM cell reconstitution.
Plasmin Activates MMP-9 in the BM
But what is the function of proteolysis in stress hematopoiesis, and what are its mediators? Plasmin can cleave proMMPs (MMP-9, MMP-12, MMP-1) (Lijnen et al., 1998a) . Here, we show that tPA either provided by BM cells or exogenously administered causes MMP activation, namely MMP-2 and MMP-9 in cultured BM stromal cells. MMPs have been identified as downstream targets for plasmin activation in other cells, e.g., at the nerve injury site (Zou et al., 2006) .
The Fibrinolytic Factor tPA Modulates Hematopoiesis by Releasing KitL
KitL is a growth factor for primitive hematopoietic cells and multiple differentiating lineages, acting in synergy with other cytokines to promote cell proliferation and differentiation. KitL is synthesized as a transmembrane protein that may be processed to produce soluble KitL (Huang et al., 1990) . We demonstrated that MMP-9 activation can promote the shedding of KitL . Here, we show that tPA indirectly via Plg and MMP activation is able to release KitL from stromal cells. Exogenous administration of recombinant tPA promotes myeloid, erythroid, and megakyaryocytic cell differentiation and progenitor proliferation. The importance of KitL for these tPA-mediated effects on hematopoiesis was supported by experiments using Sl/Sl d mice, where tPA-mediated BM cell and progenitor proliferation did not occur. Similarly, impaired BM regeneration seen in Plg À/À mice was due to an impaired compensatory increase in KitL after myelosuppression, as administration of KitL induced BM reconstitution and rescued Plgdeficient mice. Plg activation can occur via tPA, uPA, and plasma kallikrein (Lund et al., 2006) and has been implicated in cell differentiation, like myoblast fusion and differentiation (Suelves et al., 2002) or adipocyte differentiation (Selvarajan et al., 2001) .
Rebleeding has been reported after tPA treatment in ischemic stroke patients (Cheng et al., 2006) , which could stimulate HSPC proliferation (Hellman and Grate, 1967) . Therefore, it is conceivable that bleeding could have affected the outcome of our study. But no bleeding was observed after tPA administration into healthy, nonischemic mice. tPA-mediated progenitor proliferation was also observed in vitro, where bleeding can be excluded.
tPA-Mediated Effects on Hematopoietic Cells Require a Functional Microenvironment
KitL expressed in the stromal compartment is a key factor to maintain hematopoiesis. We observed reduced engraftment of either Plg À/À or Plg +/+ HSPCs into Plg À/À recipient mice, which was not due to impaired HSPC adhesion (data not shown) but due to a BM microenvironment, which could not provide KitL to support long-term hematopoiesis. The effects of a defective microenvironment are best known from studies on Sl/Sl d mice. When cells had been transplanted very early into a non-KitL defective environment, long-term repopulating activity was identical in Sl/Sl d and WT mice (Barker, 1997) . Persistence of HSCs in a defective environment resulted in progressive loss of HSC activity (Barker, 1994) .
Similar to Sl/Sl d mice, Plg À/À mice showed reduced numbers of hematopoietic progenitors, whereas the HSC compartment (cells with long-term repopulating capacity) was functionally normal. Our data indicate that Plg plays a role in cell differentiation and progenitor proliferation rather than HSC-associated self-renewal. Therefore, myelosuppression models can reveal the hematopoietic phenotype. The early death observed in Plg À/À mice after myelosuppression is most likely due to lack of cell differentiation and progenitor proliferation, as differentiated cells rather than HSCs ensure hematopoietic recovery and survival 10 days after injection of the myelosuppressive agent. Further studies will show if, aside from KitL, other growth factors are altered in Plg À/À mice. This study has implications for the control of various diseases. Plg activation is associated with cancer invasion and metastasis (Andreasen et al., 2000) . It is possible that plasmin generated in tumors activates MMPs and releases KitL, a process that could promote metastasis or angiogenesis (Kijima et al., 2002; Heissig et al., 2003) . Further studies will be necessary to evaluate this. tPA is in clinical use in the treatment of myocardial infarction (Andersen et al., 2003; Wilcox, 1996) . Its positive effect on myocardial reperfusion had been thought to be due to its fibrinolytic effects. We speculate that part of its effects after myocardial infarction is driven by KitL and its effect on hematopoietic cells. Finally, tPA can potentially be used for stem cell harvesting and might be used to expand HSPCs.
Conclusions
Activation of Plg after hematopoietic stress ( Figure 6I ) leads to activation of another protease cascade, namely MMPs. Activation of MMP-9 releases, e.g., KitL, which in turn controls hematopoietic cell proliferation and differentiation. This process helps to replenish hematopoietic cells within the BM. The involvement of the fibrinolytic system in the regulation of adult stress hematopoiesis represents a new paradigm with important implications for regenerative medicine.
EXPERIMENTAL PROCEDURES
In Vivo Assays Animals Age-(6-8 week) and sex-matched Plg +/+ and Plg À/À mice were obtained by heterozygous breeding of mice backcrossed into a C57BL/6J background (Bugge et al., 1995) . MMP-9 +/+ and MMP-9
À/À mice were used after more than ten backcrosses into CD1 mice tPA Administration In Vivo Mice were injected with human recombinant tPA (kindly provided by Eisai, Tokyo, Japan) intraperitoneally at a concentration of 1.25 3 10 6 IU = 1 mg/kg body weight daily or PBS for a total of 3 days. (Recommended tPA dosage in humans for clinical use is 10 mg/kg.) Blood and plasma samples were collected.
Peripheral Blood Analysis
Blood was collected from mice by retro-orbital bleeding using heparinized capillaries. WBC counts were determined. PBMCs were isolated from heparinized blood after centrifugation over a discontinuous gradient using lympholyte-M (Cedarlane, Ontario, Canada). Plasma samples were stored at À80 C until further analysis.
CFU-S Assay
Mobilized PBMCs were obtained and subjected to a CFU-S assay as previously described (Hattori et al., 2001 ). Mice were sacrificed on day 8. The number of visible colonies was counted.
Histological Assessment
Deparaffinized BM sections (3-5 mm) were stained for fibrin(ogen) followed by a secondary Alexa 488-labeled antibody (Molecular Probes, Inc) or with hematoxylin and eosin (H&E). BM sections were stained for MMP-9 (7-11C) as described with or without PAI-1 (2 mg/ml, Calbiochem) or MMP inhibitor (CGS 27023A, Novartis, Basel, Switzerland, 1 nM daily). Supernatants were stored at À30 C and analyzed for the release of KitL by ELISA.
Stromal-Based Expansion Cultures 1 3 10 5 linÀ cells from BM of Plg +/+ mice were cocultured with a confluent layer of stromal cells (MS-5). Recombinant tPA (5 mg/ml, daily, Cleactor R ) was added to cultures with or without KitL (2 mg/ml, every other day). Seven days later, adherent cells were retrieved using trypsin (Sigma) and pooled with the nonadherent cells. Hematopoietic cells were counted and subjected to a progenitor assay. Suspension Culture BM-derived linÀ cells (1.0 3 10 5) from Plg +/+ mice were cultured in serum-free medium for 4 days in the presence/absence of recombinant tPA (1 or 5 mg/ml, Cleactor R , Eisai Co, Japan) plus or minus recombinant KitL (2 mg/ml, PeproTech) daily added to the cultures. Cells were harvested, counted, and subjected to a progenitor cell assay. Proliferation Blocking Experiment LinÀ cells (1.2 3 10 5 ) were isolated from the BM of Plg +/+ mice and cocultured with MS-5 stromal cells in the presence/absence of recombinant tPA (5 ug/ml, Cleactor R ) with or without blocking antibodies against c-Kit (clone ASK, final concentration 0.5 mg/ml), against SCF (KitL, final concentration 0.5 mg/ml, R & D Systems), with or without PAI-1 (2 mg/ml, Calbiochem), or the MMP inhibitor (1 nM, CGS 27023A, Novartis, Basel, Switzerland) daily. The adherent and nonadherent cells collected after 5 days of culture. After counting, hematopoietic cells were subjected to a hematopoietic progenitor assay. Substrate Zymography Supernatants were treated with gelatin-agarose beads and processed through sodium dodecyl sulfate polyacrylamide gel electrophoresis as described A pro-MMP-2 standard (Oncogene Research Products, Cambridge, MA) was used to determine the molecular weight of gelatinolytic bands.
RNA Extraction and RT-PCR Analysis
Total RNAs were extracted from 4-week-old LTC stroma and MS-5 cells using Trizol reagent. RT-PCR was performed using One Step RNA PCR Kit (AMC) (TaKaRa Shuzo Co., Japan). b-actin primers 5 0 -TGGAATCCTGTGGCATCCATGAAAC-3 0 (sense strand) and 5 0 -TAAAA CGCAGCTCAGTAACAGTCCG-3 0 (antisense strand) were used to test the integrity of the total RNA extracted (349 bp product). Primer sequences for tPA were 5 0 -CTGAGGTCACAGTCCAAGCAATGT-3 0 (sense primer) and 5 0 -GCTCACGAAGATGATGGTGTAAAGA-3 0 (antisense), yielding a 564 bp product. Primer sequences for plasminogen were 5 0 -TGTGGGCTCTAAAGATGGAACTCC-3 0 (sense primer) and 5 0 -GACAAGGGGACTCGCTGGATGGCTA-3 0 (antisense primer), yielding a product of 268 bp.
FACS Analysis
BM cells of Plg +/+ and Plg À/À mice were incubated with CD11b-FITC and Gr-1-PE antibodies and analyzed by FACS. BM cell ploidy was analyzed using FACS after cell fixation with ethanol and labeling with propidium iodide (PI). For cell-cycle analysis, whole BM cells were labeled with Sca-1-FITC and stained with PI (Molecular Probes, OR) as described . BM cells of untreated and tPA-treated Plg +/+ mice were stained with CD11b-FITC and Gr-1-PE or CD71-FITC and Ter119-PE antibodies and analyzed by FACS. Next, linÀ BM cells were stained with Sca-1-FITC and PI before cell-cycle analysis was performed. For SP cell analysis, BM cells were subjected to FACS (BD Biosciences) by using the MoFlo (DakoCytomation) with the following filter sets: 405/30 bandpass (BP) to detect Hoechst blue, 585/42 BP to detect Hoechst red, and a 440 nm long-pass dichromic filter to separate Hoechst red from Hoechst blue. A subset of cells treated with verapamil confirmed the identity of the SP gate.
Immunoassay for KitL, proMMP-9, and Active MMP-9 In plasma or culture supernatants, KitL (SCF) was measured using commercially available ELISA (R & D Systems). Active MMP-9 was analyzed using the MMP-9 Activity Assay Biotrak System ELISA (Amersham Biosciences, UK).
Statistical Analysis
Results are expressed as mean ± SEM (standard error of mean). Data were analyzed using the unpaired two-tailed Student's t test. P values of <0.05 were considered significant.
Supplemental Data
Supplemental Data include one figure and can be found with this article online at http://www.cellstemcell.com/cgi/content/full/1/6/ 658/DC1/.
